Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1003 in advanced solid tumors
NCT05862831Phase 2Recruiting
- Sponsor
- Biotheus
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PM1003 in solid tumor (advanced stage), sponsored by Biotheus. Started Sep 2021; status: recruiting.
02
Drugs
PM1003
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05862831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862831.